Showing results (1461-1470 of 1,518) with videos related to

Sort By:
Pageof 152
The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Nature Communications|December 10, 2025
Limitations in PPARα-dependent mitochondrial programming restrain the differentiation of human stem cell-derived β cellsAnne C Lietzke, Emily M Walker, Elizabeth Bealer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
Translational Lung Cancer Research|May 20, 2021
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinomaDaniel Kazdal, Eugen Rempel, Cristiano Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCChristian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.
Pageof 152